You've probably heard about Ozempic and the GLP-1 wave. Cagrilintide works through a completely different pathway — and the combo data is turning heads. Here's what it actually is.
Research purposes only. Everything on this page is based on published research and is for educational purposes only. This is not medical advice. Talk to a doctor before doing anything with any compound.
Cagrilintide is a long-acting analog of amylin — a hormone your pancreas naturally produces alongside insulin. It was developed by Novo Nordisk, the same company behind Ozempic and Wegovy. Unlike those drugs, cagrilintide doesn't touch GLP-1 receptors at all. It's a completely different mechanism.
You may have heard of it as part of CagriSema — a fixed-ratio combination of cagrilintide and semaglutide that Novo Nordisk is running through late-stage trials. That combination is what most of the buzz is about, but cagrilintide has been studied on its own too.
The short version: It's an amylin-based weight loss compound from Novo Nordisk being studied solo and in combination with semaglutide. The combo data is showing results that exceed either drug alone — which is why researchers are paying attention.
In Phase 2 trials, cagrilintide as a standalone produced up to 15.6% body weight reduction at the highest dose. For context, that's in the same range as semaglutide's 14-15% from STEP trials. Combined with semaglutide as CagriSema, the numbers climb higher still.
Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells. In healthy people it does three things after meals: slows gastric emptying, suppresses glucagon, and signals satiety to the brain. In people with type 2 diabetes or obesity, amylin signaling is typically impaired.
Cagrilintide mimics and extends this natural signal. Here's what that looks like in practice:
Cagrilintide binds calcitonin receptor (CALCR) combined with receptor activity-modifying proteins RAMP1 and RAMP3 — the same receptor complex natural amylin uses. This is entirely separate from GLP-1 receptors.
Activates area postrema and nucleus tractus solitarius in the brainstem — regions that process satiety signals. The result is reduced hunger and caloric intake via a pathway GLP-1 agonists don't fully engage.
Slows gastric emptying independently of GLP-1, and suppresses postprandial glucagon secretion — helping keep blood glucose stable after meals.
Native amylin has a half-life of minutes. Cagrilintide's fatty acid chain modification enables albumin binding, extending half-life to approximately 7 days — enabling once-weekly dosing.
The key thing here is mechanistic independence from GLP-1. When you combine cagrilintide with a GLP-1 agonist like semaglutide, you're hitting two distinct receptor systems — which is why the combination shows additive (and potentially more than additive) effects.
The primary Phase 2 standalone trial enrolled 706 adults with obesity and ran 26 weeks. Key findings:
The dose-response relationship was clear — higher doses produced greater weight loss, with the 2.4mg group showing the strongest results. Most weight loss occurred through reduced caloric intake rather than increased energy expenditure.
Notable: Cagrilintide's side effect profile was generally favorable. GI effects (nausea, vomiting) were dose-dependent but generally mild to moderate — and importantly, not as prominent as those typically seen with high-dose GLP-1 agonists at equivalent efficacy levels.
The more compelling data comes from the combination studies. A Phase 2 trial of CagriSema (cagrilintide 2.4mg + semaglutide 2.4mg) at 32 weeks showed approximately 15.6% weight loss — and critically, this was superior to either component alone at matched doses. Phase 3 trials (REDEFINE program) are underway targeting this combination directly.
The additive effect makes mechanistic sense: GLP-1 receptors and amylin receptors are both present in key appetite-regulating brain regions, but they're separate systems. Saturating one doesn't block the other.
This is the question most researchers ask first. Here's the honest comparison:
The practical implication for researchers is that cagrilintide isn't a replacement for semaglutide or tirzepatide — it's a complementary mechanism. That's what makes CagriSema interesting: you're not doubling down on the same receptor, you're stacking two different pathways.
Important context: GLP-1 drugs have years of cardiovascular outcome data and FDA approval. Cagrilintide does not. For researchers comparing these compounds, the GLP-1 evidence base is substantially more mature.
CagriSema is a fixed-dose co-formulation of cagrilintide (2.4mg) and semaglutide (2.4mg) being developed by Novo Nordisk as a single weekly injection. It is not the same as taking both separately — the formulation is designed for co-administration in one pen.
The REDEFINE Phase 3 program includes multiple trials across different populations (obesity, type 2 diabetes, cardiovascular risk). This is the primary path to potential FDA approval for cagrilintide as part of a combination product.
For researchers studying the compounds individually, the Phase 2 data provides mechanistic and efficacy context, but the clinical trajectory is toward the combination product rather than cagrilintide as a standalone prescription drug.
Based on Phase 2 trial designs, cagrilintide research protocols typically use a titration schedule to minimize GI side effects. This is not a prescribing recommendation — it's a summary of how published trials have been structured.
Phase 2 protocols typically begin here for the first 4 weeks. At this dose, GI effects are minimal and the body adapts to the amylin receptor stimulation.
Step-wise increases — 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg — mirroring the approach used in GLP-1 titrations. Hold at any dose if GI effects are not well-tolerated.
The target dose used in the highest-efficacy Phase 2 arm. Once-weekly SubQ injection. The 7-day half-life makes day-of-week flexibility reasonable.
Reconstitution note: Cagrilintide is available from research vendors as a lyophilized powder requiring reconstitution with bacteriostatic water. Standard reconstitution protocol applies — see the reconstitution guide for full details.
Price comparison across vetted domestic vendors with discount codes and Certificates of Analysis.